Getting to product completion is hard. But the transition from a functional product to consistent commercial traction is a separate challenge, and one that science-led companies often underestimate.
You need to know exactly who you're selling to, why they'll buy, what they'll pay, and how you'll reach them. You need to manage the relationships with clinical partners, distributors, regulators, and boards that determine whether your launch sticks. And you need to do all of this while continuing to build.
We have launched CE-marked products, designed reimbursement strategies, managed cross-functional teams through commercial launches, and built go-to-market plans for companies entering entirely new markets. We know what this phase actually requires.
Understanding your market landscape, identifying your differentiation, and defining your value proposition.
Planning your market entry, including pricing, channel strategy, partnership development, and initial customer acquisition.
Managing relationships with investors, board members, clinical partners, and regulatory bodies.
Identifying and negotiating strategic partnerships with distributors, healthcare providers, technology platforms, and industry bodies.
Go-to-market engagements are typically structured as defined projects tied to a launch date or market entry event. For companies in active commercial build-out, retained advisory or fractional commercial leadership is often the better model.